Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2020-03-05 AGM Information
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Samil Pharmaceutical. It contains the agenda for the 67th Annual General Meeting, including the approval of financial statements, election of directors, and other corporate governance matters. It also includes detailed management information and financial statements (balance sheet, income statement, etc.) as part of the proxy materials provided to shareholders. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to vote on agenda items.
2020-03-05 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company, Samil Pharmaceutical, is holding its AGM on a date designated as a 'concentrated date' by the Korea Listed Companies Association. Since this is a specific regulatory disclosure regarding meeting logistics and compliance with the voluntary distribution program, and does not fit into the specific AGM presentation or proxy solicitation categories, it is best classified as a general regulatory filing.
2020-03-05 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Proxy Solicitation' (위임권유) for the 67th Annual General Meeting of Samil Pharmaceutical. It contains details about the meeting date, location, agenda items (approval of financial statements), and proxy voting procedures. While it includes financial statement summaries, the primary purpose of this specific filing is to solicit proxies from shareholders for the upcoming general meeting, which aligns with the definition of a Proxy Solicitation & Information Statement.
2020-02-27 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Samil Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, the payment date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-02-20 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Samil Pharmaceutical. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and appointment of audit committee members. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of meeting details and agenda items for voting purposes.
2020-02-20 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in the company's stock price. This type of filing, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but rather a direct disclosure of a financial event affecting the company's capital structure.
2020-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.